ABBOTT PARK, Ill., April 17, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2019.
- First-quarter worldwide sales of $7.5 billion increased 2.0 percent on a reported basis and 7.1 percent on an organic* basis.
- Reported diluted EPS from continuing operations under GAAP was $0.38 in the first quarter.
- Adjusted diluted EPS from continuing operations, which excludes specified items, was $0.63, above the previous guidance range.
- Abbott projects full-year 2019 diluted EPS from continuing operations on a GAAP basis of $1.95 to $2.05. Projected full-year adjusted diluted EPS from continuing operations remains unchanged at $3.15 to $3.25, reflecting double-digit growth at the mid-point.
- During the quarter, Abbott received U.S. FDA approval for a new, expanded indication for its market-leading MitraClip® device to treat clinically significant secondary mitral regurgitation, a leaky heart valve resulting from advanced heart failure.
- In January, Abbott announced U.S. FDA approval of its TactiCath® Contact Force Ablation Catheter, Sensor Enabled™, which is designed to help physicians accurately and effectively treat atrial fibrillation, a form of irregular heartbeat.
- In March, Abbott obtained CE Mark for its Alinity® m (molecular) diagnostics system and testing assays, providing market-leading speed and accuracy to help laboratories meet the growing demand for infectious disease testing.
“We’re right on track with our expectations to start the year,” said Miles D. White, chairman and chief executive officer, Abbott. “All of our key long-term growth drivers are performing well and we’re targeting another year of strong sales and earnings growth.”
|
* See note on organic growth below. |
FIRST-QUARTER BUSINESS OVERVIEW
Note: Management believes that measuring sales growth rates on an organic basis is an appropriate way for investors to best understand the underlying performance of the business.
Organic sales growth:
- Excludes the prior year first-quarter results for a non-core business within U.S. Adult Nutrition, which was discontinued during the third quarter 2018; and
- Excludes the impact of foreign exchange.
Following are sales by business segment and commentary for the first quarter:
|
Total Company |
||||||||||||||||||
|
($ in millions) |
||||||||||||||||||
|
% Change vs. 1Q18 |
||||||||||||||||||
|
Sales 1Q19 |
Reported |
Organic |
||||||||||||||||
|
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||||||
|
Total * |
2,754 |
4,781 |
7,535 |
2.9 |
1.4 |
2.0 |
3.6 |
9.0 |
7.1 |
|||||||||
|
Nutrition |
747 |
1,045 |
1,792 |
(1.5) |
4.7 |
2.0 |
0.8 |
11.1 |
6.7 |
|||||||||
|
Diagnostics |
724 |
1,117 |
1,841 |
3.3 |
(1.7) |
0.2 |
3.3 |
5.1 |
4.4 |
|||||||||
|
Established Pharmaceuticals |
— |
992 |
992 |
n/a |
(4.9) |
(4.9) |
n/a |
5.4 |
5.4 |
|||||||||
|
Medical Devices |
1,275 |
1,620 |
2,895 |
5.5 |
5.5 |
5.5 |
5.5 |
12.6 |
9.5 |
|||||||||
|
* Total Q1 2019 Abbott sales from continuing operations include Other sales of $15 million. |
|
n/a = Not Applicable. |
|
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. |
First-quarter 2019 worldwide sales of $7.5 billion increased 2.0 percent on a reported basis. On an organic basis, worldwide sales increased 7.1 percent. Refer to table titled “Non-GAAP Reconciliation of Adjusted Historical Revenue” for a reconciliation of adjusted historical revenue.
|
Nutrition |
||||||||||||||||||
|
($ in millions) |
||||||||||||||||||
|
% Change vs. 1Q18 |
||||||||||||||||||
|
Sales 1Q19 |
Reported |
Organic |
||||||||||||||||
|
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||||||
|
Total |
747 |
1,045 |
1,792 |
(1.5) |
4.7 |
2.0 |
0.8 |
11.1 |
6.7 |
|||||||||
|
Pediatric |
453 |
576 |
1,029 |
1.2 |
5.4 |
3.5 |
1.2 |
11.2 |
6.7 |
|||||||||
|
Adult |
294 |
469 |
763 |
(5.5) |
3.9 |
0.1 |
0.2 |
11.1 |
6.8 |
|||||||||
Worldwide Nutrition sales increased 2.0 percent on a reported basis in the first quarter. On an organic basis, sales increased 6.7 percent. Refer to table titled “Non-GAAP Reconciliation of Adjusted Historical Revenue” for a reconciliation of adjusted historical revenue.
Worldwide Pediatric Nutrition sales increased 3.5 percent on a reported basis in the first quarter, including an unfavorable 3.2 percent effect of foreign exchange, and increased 6.7 percent on an organic basis. International Pediatric Nutrition sales increased 5.4 percent on a reported basis and 11.2 percent on an organic basis in the first quarter. Sales performance in the quarter was led by strong growth in Asia and Latin America, including broad-based growth across Abbott’s portfolio of infant and toddler brands.
Worldwide Adult Nutrition sales increased 0.1 percent on a reported basis in the first quarter, and increased 6.8 percent on an organic basis. International Adult Nutrition sales increased 3.9 percent on a reported basis and 11.1 percent on an organic basis in the first quarter. Sales performance in the quarter was led by strong growth of Ensure®, Abbott’s market-leading complete and balanced nutrition brand, and Glucerna®, Abbott’s market-leading diabetes-specific nutrition brand.
|
Diagnostics |
||||||||||||||||||
|
($ in millions) |
||||||||||||||||||
|
% Change vs. 1Q18 |
||||||||||||||||||
|
Sales 1Q19 |
Reported |
Organic |
||||||||||||||||
|
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||||||
|
Total |
724 |
1,117 |
1,841 |
3.3 |
(1.7) |
0.2 |
3.3 |
5.1 |
4.4 |
|||||||||
|
Core Laboratory |
249 |
812 |
1,061 |
9.3 |
2.7 |
4.1 |
9.3 |
10.0 |
9.9 |
|||||||||
|
Molecular |
40 |
68 |
108 |
4.2 |
(14.5) |
(8.4) |
4.2 |
(9.7) |
(5.1) |
|||||||||
|
Point of Care |
109 |
26 |
135 |
(1.7) |
(16.0) |
(4.8) |
(1.7) |
(13.1) |
(4.2) |
|||||||||
|
Rapid Diagnostics |
326 |
211 |
537 |
0.6 |
(10.3) |
(4.0) |
0.6 |
(4.2) |
(1.4) |
|||||||||
Worldwide Diagnostics sales increased 0.2 percent on a reported basis in the first quarter, including an unfavorable 4.2 percent effect of foreign exchange, and increased 4.4 percent on an organic basis.
Core Laboratory Diagnostics sales increased 4.1 percent on a reported basis and 9.9 percent on an organic basis in the first quarter. Sales performance in the quarter was led by above-market growth in the U.S. and internationally, where Abbott is achieving continued strong adoption of its Alinity family of innovative and highly differentiated diagnostic instruments.
Molecular Diagnostics sales decreased 8.4 percent on a reported basis in the first quarter, including an unfavorable 3.3 percent effect of foreign exchange, and decreased 5.1 percent on an organic basis. International sales growth in Molecular and Rapid Diagnostics was negatively impacted in the quarter by certain non-governmental organization (NGO) purchasing patterns in Africa. During the quarter, Abbott obtained CE Mark for its Alinity m (molecular) diagnostics system and several testing assays, providing market-leading speed and accuracy to help laboratories meet the growing demand for infectious disease testing.
Point of Care Diagnostics sales decreased 4.8 percent on a reported basis in the first quarter, including an unfavorable 0.6 percent effect of foreign exchange, and decreased 4.2 percent on an organic basis.
Rapid Diagnostics sales decreased 4.0 percent on a reported basis in the first quarter, including an unfavorable 2.6 percent effect of foreign exchange, and decreased 1.4 percent on an organic basis. Strong sales growth in several areas of the business, including cardio-metabolic testing and Abbott’s ID-NOW TM infectious disease testing platform, was offset by a difficult comparison versus the first-quarter of 2018 when sales were abnormally high due to a strong flu season.
|
Established Pharmaceuticals |
||||||||||||||||||
|
($ in millions) |
||||||||||||||||||
|
% Change vs. 1Q18 |
||||||||||||||||||
|
Sales 1Q19 |
Reported |
Organic |
||||||||||||||||
|
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||||||
|
Total |
— |
992 |
992 |
n/a |
(4.9) |
(4.9) |
n/a |
5.4 |
5.4 |
|||||||||
|
Key Emerging Markets |
— |
752 |
752 |
n/a |
(5.2) |
(5.2) |
n/a |
7.3 |
7.3 |
|||||||||
|
Other |
— |
240 |
240 |
n/a |
(4.2) |
(4.2) |
n/a |
(0.9) |
(0.9) |
|||||||||
Established Pharmaceuticals sales decreased 4.9 percent on a reported basis in the first quarter, including an unfavorable 10.3 percent effect of foreign exchange, and increased 5.4 percent on an organic basis.
Key Emerging Markets include India, Brazil, Russia and China along with several additional emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies decreased 5.2 percent on a reported basis in the first quarter, including an unfavorable 12.5 percent effect of foreign exchange, and increased 7.3 percent on an organic basis led by growth in several markets.
Other sales decreased 4.2 percent on a reported basis in the first quarter, including an unfavorable 3.3 percent effect of foreign exchange, and decreased 0.9 percent on an organic basis. As expected, Other sales growth was negatively impacted in the quarter by the recent discontinuation of a non-core, low-margin supply agreement.
|
Medical Devices |
||||||||||||||||||
|
($ in millions) |
||||||||||||||||||
|
% Change vs. 1Q18 |
||||||||||||||||||
|
Sales 1Q19 |
Reported |
Organic |
||||||||||||||||
|
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
U.S. |
Int’l |
Total |
||||||||||
|
Total |
1,275 |
1,620 |
2,895 |
5.5 |
5.5 |
5.5 |
5.5 |
12.6 |
9.5 |
|||||||||
|
Cardiovascular and Neuromodulation |
1,123 |
1,206 |
2,329 |
0.1 |
0.4 |
0.2 |
0.1 |
6.9 |
3.6 |
|||||||||
|
Rhythm Management |
233 |
257 |
490 |
(11.6) |
(5.5) |
(8.5) |
(11.6) |
1.0 |
(5.2) |
|||||||||
|
Electrophysiology |
193 |
236 |
429 |
5.7 |
13.3 |
9.8 |
5.7 |
19.5 |
13.1 |
|||||||||
|
Heart Failure |
143 |
41 |
184 |
26.1 |
5.7 |
20.9 |
26.1 |
12.4 |
22.6 |
|||||||||
|
Vascular |
266 |
443 |
709 |
(6.9) |
(2.3) |
(4.1) |
(6.9) |
3.7 |
(0.4) |
|||||||||
|
Structural Heart |
136 |
188 |
324 |
24.8 |
1.8 |
10.3 |
24.8 |
9.3 |
15.0 |
|||||||||
|
Neuromodulation |
152 |
41 |
193 |
(9.6) |
(6.1) |
(8.9) |
(9.6) |
2.1 |
(7.1) |
|||||||||
|
Diabetes Care |
152 |
414 |
566 |
76.5 |
23.7 |
34.4 |
76.5 |
33.1 |
42.0 |
|||||||||
|
Vascular Product Lines: |
||||||||||||||||||
|
Coronary and Endovasculara) |
235 |
440 |
675 |
(2.7) |
(2.1) |
(2.3) |
(2.7) |
3.8 |
1.6 |
|||||||||
|
a) |
Includes drug-eluting stents, balloon catheters, guidewires, vascular imaging/diagnostics products, vessel closure, carotid and other coronary and peripheral products. |
Worldwide Medical Devices sales increased 5.5 percent on a reported basis in the first quarter and increased 9.5 percent on an organic basis, led by double-digit growth in Electrophysiology, Heart Failure, Structural Heart and Diabetes Care.
In Electrophysiology, in January, Abbott announced U.S. FDA approval of its TactiCath Contact Force Ablation Catheter, Sensor Enabled, which is designed to help physicians accurately and effectively treat atrial fibrillation, a form of irregular heartbeat.
In Heart Failure, growth was driven by rapid U.S. market adoption of Abbott’s HeartMate 3® left ventricular assist device following FDA approval as a destination (long-term use) therapy in late-2018. In March, Abbott announced data from its MOMENTUM 3 clinical study, the largest randomized controlled trial to assess outcomes in patients receiving a heart pump to treat advanced heart failure, which demonstrated HeartMate 3 improved survival and clinical outcomes in this patient population.
Growth in Structural Heart was broad-based across several areas of the business, including MitraClip, Abbott’s market-leading device for the minimally invasive treatment of mitral regurgitation (MR), a leaky heart valve. During the quarter, Abbott received U.S. FDA approval for a new, expanded indication for MitraClip to treat clinically significant secondary MR as a result of underlying heart failure. This new indication significantly expands the number of people with MR that can be treated with the MitraClip device.
In Diabetes Care, sales increased 34.4 percent on a reported basis and 42.0 percent on an organic basis in the first quarter. Sales growth in the quarter was led by FreeStyle® Libre®, Abbott’s revolutionary continuous glucose monitoring system, with worldwide sales of $379 million, an increase of 70.2 percent on a reported basis and 80.1 percent on an organic basis versus the prior year. During the quarter, Abbott released real-world data from nearly 500,000 users that shows higher rates of scanning with its FreeStyle Libre system improves glucose control for people living with diabetes.
ABBOTT’S EARNINGS-PER-SHARE GUIDANCE
Abbott projects 2019 diluted earnings per share from continuing operations under Generally Accepted Accounting Principles (GAAP) of $1.95 to $2.05. Abbott forecasts net specified items for the full year 2019 of $1.20 per share. Specified items include intangible amortization expense, acquisition-related expenses, charges associated with cost reduction initiatives and other expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $3.15to $3.25 for the full year 2019.
Abbott is issuing second-quarter 2019 guidance for diluted earnings per share from continuing operations under GAAP of $0.47 to $0.49. Abbott forecasts specified items for the second quarter 2019 of $0.32 per share primarily related to intangible amortization, acquisition-related expenses, cost reduction initiatives and other expenses. Excluding specified items, projected adjusted diluted earnings per share from continuing operations would be $0.79 to $0.81 for the second quarter.
ABBOTT DECLARES 381ST CONSECUTIVE QUARTERLY DIVIDEND
On Feb. 22, 2019, the board of directors of Abbott declared the company’s quarterly dividend of $0.32 per share. Abbott’s cash dividend is payable May 15, 2019, to shareholders of record at the close of business on April 15, 2019.
Abbott has increased its dividend payout for 47 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.
About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 103,000 colleagues serve people in more than 160 countries.
Connect with us at www.abbott.com, on LinkedIn at www.linkedin.com/company/abbott-/, on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews and @AbbottGlobal.
Abbott will webcast its live first-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later that day.
— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements
Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” to our Annual Report on Securities and Exchange Commission Form 10-K for the year ended Dec. 31, 2018, and are incorporated by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
|
Abbott Laboratories and Subsidiaries |
|||||||
|
Condensed Consolidated Statement of Earnings |
|||||||
|
First Quarter Ended March 31, 2019 and 2018 |
|||||||
|
(in millions, except per share data) |
|||||||
|
(unaudited) |
|||||||
|
1Q19 |
1Q18 |
% Change |
|||||
|
Net Sales |
$7,535 |
$7,390 |
2.0 |
||||
|
Cost of products sold, excluding amortization expense |
3,160 |
3,067 |
3.0 |
||||
|
Amortization of intangible assets |
486 |
584 |
(16.8) |
||||
|
Research and development |
672 |
589 |
14.2 |
1) |
|||
|
Selling, general, and administrative |
2,478 |
2,542 |
(2.6) |
||||
|
Total Operating Cost and Expenses |
6,796 |
6,782 |
0.2 |
||||
|
Operating earnings |
739 |
608 |
21.6 |
||||
|
Interest expense, net |
148 |
199 |
(26.2) |
||||
|
Net foreign exchange (gain) loss |
6 |
(3) |
n/m |
||||
|
Debt extinguishment costs |
— |
14 |
n/m |
||||
|
Other (income) expense, net |
(47) |
(33) |
38.0 |
||||
|
Earnings from Continuing Operations before taxes |
632 |
431 |
46.8 |
||||
|
Tax expense (benefit) on Earnings from Continuing Operations |
(40) |
22 |
n/m |
2) |
|||
|
Earnings from Continuing Operations |
672 |
409 |
64.3 |
||||
|
Earnings from Discontinued Operations, net of taxes |
— |
9 |
n/m |
||||
|
Net Earnings |
$672 |
$418 |
60.8 |
||||
|
Earnings from Continuing Operations, excluding |
|||||||
|
Specified Items, as described below |
$1,126 |
$1,050 |
7.2 |
3) |
|||
|
Diluted Earnings per Common Share from: |
|||||||
|
Continuing Operations |
$0.38 |
$0.23 |
65.2 |
||||
|
Discontinued Operations |
— |
— |
n/m |
||||
|
Total |
$0.38 |
$0.23 |
65.2 |
||||
|
Diluted Earnings per Common Share from Continuing |
|||||||
|
Operations, excluding Specified Items, as described below |
$0.63 |
$0.59 |
6.8 |
3) |
|||
|
Average Number of Common Shares Outstanding |
|||||||
|
Plus Dilutive Common Stock Options |
1,777 |
1,765 |
|||||
|
NOTES: |
|
|
See tables titled “Non-GAAP Reconciliation of Financial Information From Continuing Operations” for an explanation of certain non-GAAP financial information. |
|
|
n/m = Percent change is not meaningful. |
|
|
See footnotes below. |
|
|
1) |
In the first quarter of 2019, in conjunction with the acquisition of Cephea Valve Technologies, Inc., Abbott acquired an R&D asset valued at $102 million, which was immediately expensed. |
|
2) |
2019 Tax expense on Earnings from Continuing Operations includes the impact of a $78 million reduction of the transition tax associated with the Tax Cuts and Jobs Act (TCJA) and approximately $65 million in excess tax benefits associated with share-based compensation. |
|
2018 Tax expense on Earnings from Continuing Operations includes the impact of approximately $65 million in excess tax benefits associated with share-based compensation. |
|
|
3) |
2019 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $454 million, or $0.25 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions. |
|
2018 Net Earnings and Diluted Earnings per Common Share from Continuing Operations, excluding Specified Items, excludes net after-tax charges of $641 million, or $0.36 per share, for intangible amortization expense and other expenses primarily associated with acquisitions and restructuring actions. |
|
|
Abbott Laboratories and Subsidiaries |
||||||||
|
Non-GAAP Reconciliation of Financial Information From Continuing Operations |
||||||||
|
First Quarter Ended March 31, 2019 and 2018 |
||||||||
|
(in millions, except per share data) |
||||||||
|
(unaudited) |
||||||||
|
1Q19 |
||||||||
|
As |
Specified |
As |
% to |
|||||
|
Intangible Amortization |
$486 |
$(486) |
— |
|||||
|
Gross Margin |
3,889 |
527 |
$4,416 |
58.6% |
||||
|
R&D |
672 |
(115) |
557 |
7.4% |
||||
|
SG&A |
2,478 |
(45) |
2,433 |
32.3% |
||||
|
Other (income) expense, net |
(47) |
(13) |
(60) |
|||||
|
Earnings from Continuing Operations before taxes |
632 |
700 |
1,332 |
|||||
|
Tax expense (benefit) on Earnings from Continuing Operations |
(40) |
246 |
206 |
|||||
|
Earnings from Continuing Operations |
672 |
454 |
1,126 |
|||||
|
Diluted Earnings per Share from Continuing Operations |
$0.38 |
$0.25 |
$0.63 |
|||||
Specified items reflect intangible amortization expense of $486 million and other expenses of $214 million, primarily associated with acquisitions, restructuring actions and other expenses. See table titled “Details of Specified Items” for additional details regarding specified items.
|
1Q18 |
||||||||
|
As |
Specified |
As |
% to |
|||||
|
Intangible Amortization |
$584 |
$(584) |
— |
|||||
|
Gross Margin |
3,739 |
647 |
$4,386 |
59.3% |
||||
|
R&D |
589 |
(43) |
546 |
7.4% |
||||
|
SG&A |
2,542 |
(90) |
2,452 |
33.2% |
||||
|
Net foreign exchange (gain) loss |
(3) |
(1) |
(4) |
|||||
|
Debt extinguishment costs |
14 |
(14) |
— |
|||||
|
Other (income) expense, net |
(33) |
(2) |
(35) |
|||||
|
Earnings from Continuing Operations before taxes |
431 |
797 |
1,228 |
|||||
|
Tax expense on Earnings from Continuing Operations |
22 |
156 |
178 |
|||||
|
Earnings from Continuing Operations |
409 |
641 |
1,050 |
|||||
|
Diluted Earnings per Share from Continuing Operations |
$0.23 |
$0.36 |
$0.59 |
|||||
Specified items reflect intangible amortization expense of $584 million and other expenses of $213 million, primarily associated with acquisitions, restructuring actions and other expenses. See table titled “Details of Specified Items” for additional details regarding specified items.
A reconciliation of the first-quarter tax rates for continuing operations for 2019 and 2018 is shown below:
|
1Q19 |
|||||||
|
($ in millions) |
Pre-Tax |
Taxes on |
Tax |
||||
|
As reported (GAAP) |
$632 |
(40) |
(6.3%) |
1) |
|||
|
Specified items |
700 |
246 |
|||||
|
Excluding specified items |
$1,332 |
$206 |
15.5% |
||||
|
1Q18 |
|||||||
|
($ in millions) |
Pre-Tax |
Taxes on |
Tax |
||||
|
As reported (GAAP) |
$431 |
$22 |
5.0% |
2) |
|||
|
Specified items |
797 |
156 |
|||||
|
Excluding specified items |
$1,228 |
$178 |
14.5% |
||||
|
1) |
Reported tax rate on a GAAP basis for the first quarter of 2019 includes the impact of a $78 million reduction of the transition tax associated with the TCJA and approximately $65 million in excess tax benefits associated with share-based compensation. |
|
2) |
Reported tax rate on a GAAP basis for 2018 includes the impact of approximately $65 million in excess tax benefits associated with share-based compensation. |
|
Abbott Laboratories and Subsidiaries |
|||||||||||||||
|
Non-GAAP Reconciliation of Adjusted Historical Revenue |
|||||||||||||||
|
First Quarter Ended March 31, 2019 and 2018 |
|||||||||||||||
|
($ in millions) (unaudited) |
|||||||||||||||
|
1Q19 |
1Q18 |
% Change vs. 1Q18 |
|||||||||||||
|
Abbott |
Abbott |
Discontinued |
Adjusted |
Non-GAAP |
|||||||||||
|
Reported |
Reported |
Organicb) |
|||||||||||||
|
Total Company |
7,535 |
7,390 |
(17) |
7,373 |
2.0 |
2.2 |
7.1 |
||||||||
|
U.S. |
2,754 |
2,675 |
(17) |
2,658 |
2.9 |
3.6 |
3.6 |
||||||||
|
Int’l |
4,781 |
4,715 |
— |
4,715 |
1.4 |
1.4 |
9.0 |
||||||||
|
Total Nutrition |
1,792 |
1,756 |
(17) |
1,739 |
2.0 |
3.0 |
6.7 |
||||||||
|
U.S. |
747 |
758 |
(17) |
741 |
(1.5) |
0.8 |
0.8 |
||||||||
|
Int’l |
1,045 |
998 |
— |
998 |
4.7 |
4.7 |
11.1 |
||||||||
|
Adult |
763 |
762 |
(17) |
745 |
0.1 |
2.4 |
6.8 |
||||||||
|
U.S. |
294 |
310 |
(17) |
293 |
(5.5) |
0.2 |
0.2 |
||||||||
|
Int’l |
469 |
452 |
— |
452 |
3.9 |
3.9 |
11.1 |
||||||||
|
a) |
Reflects sales related to a non-core product line within the U.S. Adult Nutrition business, which was discontinued during the third quarter 2018. |
|
b) |
In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. |
|
Abbott Laboratories and Subsidiaries |
||||||||||
|
Details of Specified Items |
||||||||||
|
First Quarter Ended March 31, 2019 |
||||||||||
|
(in millions, except per share data) |
||||||||||
|
(unaudited) |
||||||||||
|
Acquisition or |
Restructuring |
Intangible |
Other (c) |
Total |
||||||
|
Gross Margin |
$ 19 |
$ 22 |
$ 486 |
$ — |
$ 527 |
|||||
|
R&D |
(7) |
(5) |
— |
(103) |
(115) |
|||||
|
SG&A |
(43) |
(2) |
— |
— |
(45) |
|||||
|
Other (income) expense, net |
(3) |
— |
— |
(10) |
(13) |
|||||
|
Earnings from Continuing Operations before taxes |
$ 72 |
$ 29 |
$ 486 |
$ 113 |
700 |
|||||
|
Tax expense on Earnings from Continuing Operations (d) |
246 |
|||||||||
|
Earnings from Continuing Operations |
$ 454 |
|||||||||
|
Diluted Earnings per Share from Continuing Operations |
$ 0.25 |
|||||||||
|
The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information From Continuing Operations”. |
|
|
a) |
Acquisition-related expenses include costs for tax and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for retention, severance, and the integration of systems, processes and business activities, and fair value adjustments to contingent consideration related to a business acquisition. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. |
|
c) |
Other expense relates to the acquisition of an R&D asset and charges related to the impairment of certain assets. |
|
d) |
Reflects the net tax benefit associated with the specified items, a reduction in the transition tax associated with the TCJA and excess tax benefits associated with share-based compensation. |
|
Abbott Laboratories and Subsidiaries |
||||||||||
|
Details of Specified Items |
||||||||||
|
First Quarter Ended March 31, 2018 |
||||||||||
|
(in millions, except per share data) |
||||||||||
|
(unaudited) |
||||||||||
|
Acquisition or |
Restructuring |
Intangible |
Other (c) |
Total |
||||||
|
Gross Margin |
$ 45 |
$ 18 |
$ 584 |
$ — |
$ 647 |
|||||
|
R&D |
(16) |
(2) |
— |
(25) |
(43) |
|||||
|
SG&A |
(86) |
(4) |
— |
— |
(90) |
|||||
|
Net foreign exchange (gain) loss |
— |
(1) |
— |
— |
(1) |
|||||
|
Debt extinguishment costs |
— |
— |
— |
(14) |
(14) |
|||||
|
Other (income) expense, net |
(2) |
— |
— |
— |
(2) |
|||||
|
Earnings from Continuing Operations before taxes |
$ 149 |
$ 25 |
$ 584 |
$ 39 |
797 |
|||||
|
Tax expense on Earnings from Continuing Operations (d) |
156 |
|||||||||
|
Earnings from Continuing Operations |
$ 641 |
|||||||||
|
Diluted Earnings per Share from Continuing Operations |
$ 0.36 |
|||||||||
|
The table above provides additional details regarding the specified items described on tables titled “Non-GAAP Reconciliation of Financial Information From Continuing Operations”. |
|
|
a) |
Acquisition-related expenses include costs for legal, accounting, tax, and other services related to business acquisitions, integration costs which represent incremental costs directly related to integrating the acquired businesses and include expenditures for consulting, retention, severance, and the integration of systems, processes and business activities, fair value adjustments to contingent consideration related to a business acquisition, and inventory step-up amortization. |
|
b) |
Restructuring and cost reduction initiative expenses include severance, outplacement, inventory write-downs, asset impairments, accelerated depreciation, and other direct costs associated with specific restructuring plans and cost reduction initiatives. Restructuring and cost reduction plans consist of distinct initiatives to streamline operations including the consolidation and rationalization of business activities and facilities, workforce reductions, the transfer of product lines between manufacturing facilities, and the transfer of other business activities between sites. |
|
c) |
Other expense relates to the acquisition of an R&D asset and the cost associated with the early extinguishment of debt. |
|
d) |
Reflects the net tax benefit associated with the specified items and excess tax benefits associated with share-based compensation. |
SOURCE Abbott
